The US FDA's request for data beyond what it deems necessary to review an abbreviated new drug application (ANDA) does not necessarily constitute a change in approval requirements that would preserve a first-filer's 180-day generic marketing exclusivity, a federal court has ruled.
In a Jan. 24 opinion, US District Judge Randolph Moss said FDA's demand for commercial-scale data for Amneal...






